About this trial
This prospective observational study aims to evaluate the prognostic value of complete blood count (CBC)-derived inflammatory indices, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII), for predicting severe acute pancreatitis and 28-day mortality in adult patients admitted with acute pancreatitis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years
Diagnosis of acute pancreatitis based on at least two of the following: characteristic abdominal pain, serum amylase or lipase ≥ 3× upper limit of normal, or imaging consistent with acute pancreatitis
Admission within 72 hours of symptom onset
Disqualifiers
Chronic pancreatitis without an acute episode
Severe immunosuppression (neutropenia < 500/mm³ or high-dose immunosuppressive therapy after solid organ transplantation)
Active non-pancreatic infection on admission requiring systemic antibiotics
Refusal to provide informed consent
Trial population
Adult patients with acute pancreatitis admitted to El-Rahgi Liver Hospital, Assiut University, who meet the study eligibility criteria.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Severe acute pancreatitis
Occurrence of severe acute pancreatitis defined as persistent organ failure lasting more than 48 hours according to the revised Atlanta criteria (using Marshall or SOFA score thresholds)
Secondary outcomes
28-day all-cause mortality
All-cause mortality within 28 days from hospital admission.
Initiation of systemic antibiotics
Proportion of patients receiving systemic antibiotics during the index hospitalization.
Duration of antibiotic therapy
Total number of days of systemic antibiotic therapy during the index hospitalization.
Infected pancreatic necrosis
Occurrence of infected pancreatic necrosis confirmed by microbiological culture or strong clinical and radiological evidence requiring intervention.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: